ArticleClinical journal of the American Society of Nephrology : CJASN2010
Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery.
Article in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02533414 (Effect of Use of Ureteral Access Sheath on Blood and Urine Levels of Netrin-1 in Patients Undergoing Retrograde Intrarenal Surgery), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Use of Ureteral Access Sheath on Blood and Urine Levels of Netrin-1 in Patients Undergoing Retrograde Intrarenal Surgery
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Urinary L-FABP as an Early Biomarker for Pediatric Acute Kidney Injury Following Cardiac Surgery with Cardiopulmonary Bypass: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Review
- Unveiling the significance of Netrin-1 and Netrin-4 in metabolic syndrome.Scientific reports · 2026Article
- Acute Kidney Injury Biomarkers in Perioperative Care: A Scoping Review of Clinical Implementation.Diagnostics (Basel, Switzerland) · 2025Review
- Transient renal tubular injury among children and adolescents during diabetic ketoacidosis: severity, renal perfusion, and urinary netrin- 1 interplay.European journal of pediatrics · 2025Article
- The usefulness of urinary netrin-1 determination as an early marker of acute kidney injury in children after cardiac surgery.Archives of medical science : AMS · 2025Article
- Insights from the neural guidance factor Netrin-1 into neurodegeneration and other diseases.Frontiers in molecular neuroscience · 2024Review
- CXCL10 is a prognostic marker for pancreatic adenocarcinoma and tumor microenvironment remodeling.BMC cancer · 2023Article
- Netrin-1: A Modulator of Macrophage Driven Acute and Chronic Inflammation.International journal of molecular sciences · 2021Review
- PMN-derived netrin-1 attenuates cardiac ischemia-reperfusion injury via myeloid ADORA2B signaling.The Journal of experimental medicine · 2021Article
- Is Urinary Netrin-1 a Good Marker of Tubular Damage in Preterm Newborns?Journal of clinical medicine · 2021Article
- Kidney Diseases: The Age of Molecular Markers.Advances in experimental medicine and biology · 2021Article
- Urinary netrin-1 concentration in healthy full-term newborns.Archives of medical science : AMS · 2021Article
- Netrin-1 works with UNC5B to regulate angiogenesis in diabetic kidney disease.Frontiers of medicine · 2020Article
- Urinary and Serum Biomarkers for Prediction of Acute Kidney Injury in Patients Undergoing Liver Transplantation.Annals of transplantation · 2019Review
- Netrin-1 alleviates subarachnoid haemorrhage-induced brain injury via the PPARγ/NF-KB signalling pathway.Journal of cellular and molecular medicine · 2019Article
- Biomarkers of Sepsis-Induced Acute Kidney Injury.BioMed research international · 2018Review
- Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes.Frontiers in endocrinology · 2018Article
- Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment.Nature reviews. Nephrology · 2017Review
- Evaluation of Netrin-1 Levels and Albuminuria in Patients With Diabetes.Journal of clinical laboratory analysis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
objectivesNetrin-1, a laminin-related axon guidance molecule, is highly induced and excreted in the urine after acute kidney injury (AKI) in animals. Here, we determined the utility of urinary netrin-1 levels to predict AKI in humans undergoing cardiopulmonary bypass (CPB). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Serial urine samples were analyzed by enzyme-linked immunosorbent assay for netrin-1 in 26 patients who developed AKI (defined as a 50% or greater increase in serum creatinine after CPB) and 34 controls (patients who did not develop AKI after CPB).
resultsUsing serum creatinine, AKI was detected on average only 48 hours after CPB. In contrast, urine netrin-1 increased at 2 hours after CPB, peaked at 6 hours (2462 +/- 370 pg/mg creatinine), and remained elevated up to 48 hours after CPB. The predictive power of netrin-1 as demonstrated by area under the receiver-operating characteristics curve for diagnosis of AKI at 2, 6, and 12 hours after CPB was 0.74, 0.86, and 0.89, respectively. The 6-hour urine netrin-1 measurement strongly correlated with duration and severity of AKI, as well as length of hospital stay (all P < 0.05). Adjusting for CPB time, the 6-hour netrin-1 remained a powerful independent predictor of AKI, with an odds ratio of 1.20 (95% confidence interval: 1.08 to 1.41; P = 0.006).
conclusionOur results suggest that netrin-1 is an early, predictive biomarker of AKI after CPB and may allow for the reliable early diagnosis and prognosis of AKI after CPB, before the rise in serum creatinine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.